SMS Pharmaceuticals Ltd. Files SEBI Compliance Certificate for Q1 FY27
SMS Pharmaceuticals Limited submitted a compliance certificate for Q1 FY27 under SEBI regulations. The company's RTA confirmed timely dematerialization of securities and updated ownership records for the period ending June 30, 2026.
This is a standard compliance filing as required by SEBI regulations and does not involve any new financial disclosures, corporate actions, or strategic changes that would materially impact the company.
The announcement is a routine regulatory filing and does not contain any new financial information or significant business developments that would impact the company's sentiment.
SMS Pharmaceuticals Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, to the stock exchanges. This certificate, received from their Registrar and Share Transfer Agent, M/s. Aarthi Consultants Private Limited, confirms compliance for the quarter ended June 30, 2026.
The company and its RTA have confirmed that all actions required for the dematerialization of securities were completed within 15 days of receiving the certificates from depository participants during the period from April 1, 2026, to June 30, 2026. This includes the mutilation and cancellation of original certificates, and updating the records to reflect the depository as the registered owner. The securities involved are listed on the stock exchanges.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.